arrow
C

Cem Akin

university of michigan
H指数:69
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years

阿伐普利替尼在3年内为惰性系统性肥大细胞增生症患者实现长期疾病控制且安全性良好

2026-04-140
OAAI
Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation

KIT D816V在过敏性休克或系统性肥大细胞活化中的流行率

2025-10-250
OAAI
The state of the academic medical center in allergy/immunology: Work Group Report of the AAAAI A/I Division Directors Committee

过敏/免疫学领域学术医疗中心的发展现状:AAAAI过敏/免疫科主任委员会工作组报告

2025-07-310
PRE
Continued symptom and quality of life improvement with favorable safety shown with long-term avapritinib in indolent systemic mastocytosis

长期使用avapritinib治疗惰性系统性肥大细胞增生症显示出持续的疗效和生存质量改善,以及良好的安全性。

2025-05-220
PREAI
Current status and future directions in food protein-induced enterocolitis syndrome: An NIAID workshop report of the June 22, 2022, virtual meeting

食物蛋白诱导的过敏性肠结肠炎综合征的现状与未来方向:NIAID 2022年6月22日虚拟会议工作报告

2025-02-010
PRE
Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
2024-12-012
OAAI
Mast cell activation syndrome: Current understanding and research needs

肥大细胞活化综合征: 当前的理解和研究需求

2024-08-010
PRE